Datasets:

ClarusC64
/

pharma-program-go-no-go-coherence-risk-v0.1

uid stringclasses 10 values	dataset_id stringclasses 1 value	year int64 2.02k 2.02k	therapeutic_area stringclasses 6 values	program_stage stringclasses 1 value	efficacy_signal_present stringclasses 2 values	safety_margin_ok stringclasses 2 values	biomarker_support stringclasses 2 values	target_validity stringclasses 3 values	portfolio_fit stringclasses 2 values	team_narrative_strength stringclasses 10 values	question stringclasses 1 value	ground_truth_label stringclasses 2 values	ground_truth_rationale stringclasses 10 values	outcome_signal stringclasses 2 values	source_citation stringclasses 1 value
GN-TR-001	pharma-program-go-no-go-coherence-risk-v0.1	2,024	Oncology	Phase2	yes	yes	yes	strong	yes	Narrative matches data and portfolio need.	Should program proceed. Answer go or no_go.	go	Aligned biology and signal.	advance	Synthetic
GN-TR-002	pharma-program-go-no-go-coherence-risk-v0.1	2,024	Oncology	Phase2	no	no	no	weak	no	Narrative optimistic despite weak data.	Should program proceed. Answer go or no_go.	no_go	Weak efficacy and safety.	terminate	Synthetic
GN-TR-003	pharma-program-go-no-go-coherence-risk-v0.1	2,023	Cardiology	Phase2	yes	yes	yes	strong	yes	Signal consistent across endpoints.	Should program proceed. Answer go or no_go.	go	Consistent efficacy and safety.	advance	Synthetic
GN-TR-004	pharma-program-go-no-go-coherence-risk-v0.1	2,023	Cardiology	Phase2	no	yes	no	medium	no	Marginal efficacy and no biomarker support.	Should program proceed. Answer go or no_go.	no_go	Insufficient benefit.	terminate	Synthetic
GN-TR-005	pharma-program-go-no-go-coherence-risk-v0.1	2,022	Neurology	Phase2	yes	yes	yes	strong	yes	Clear responder subgroup.	Should program proceed. Answer go or no_go.	go	Signal in enriched population.	advance	Synthetic
GN-TR-006	pharma-program-go-no-go-coherence-risk-v0.1	2,022	Neurology	Phase2	no	no	no	weak	no	No clinical improvement.	Should program proceed. Answer go or no_go.	no_go	No signal present.	terminate	Synthetic
GN-TR-007	pharma-program-go-no-go-coherence-risk-v0.1	2,021	Rheumatology	Phase2	yes	yes	yes	strong	yes	Dose response and safety acceptable.	Should program proceed. Answer go or no_go.	go	Aligned package.	advance	Synthetic
GN-TR-008	pharma-program-go-no-go-coherence-risk-v0.1	2,021	Rheumatology	Phase2	no	yes	no	weak	no	Minimal improvement.	Should program proceed. Answer go or no_go.	no_go	No meaningful efficacy.	terminate	Synthetic
GN-TR-009	pharma-program-go-no-go-coherence-risk-v0.1	2,020	Infectious Disease	Phase2	yes	yes	yes	strong	yes	Strong pathogen clearance.	Should program proceed. Answer go or no_go.	go	Clear benefit.	advance	Synthetic
GN-TR-010	pharma-program-go-no-go-coherence-risk-v0.1	2,020	Metabolic	Phase2	no	no	no	weak	no	No glucose control improvement.	Should program proceed. Answer go or no_go.	no_go	No efficacy.	terminate	Synthetic

What this repo is for

support go or stop decisions in drug programs

detect when teams continue weak assets

detect when strong assets are wrongly killed

align biology, safety, and signal with decision

reduce sunk-cost bias

support portfolio governance boards

support licensing and diligence reviews

How it is used

You provide one row describing a program.

The system returns one label.

go or no_go

How to read the output

go means

efficacy signal present

safety acceptable

biomarker supports

target valid

dose workable

narrative matches data

no_go means

weak or absent efficacy

safety margin poor

biomarker not predictive

target weak

narrative stronger than evidence

continuation driven by momentum

Who uses it

portfolio committees

clinical leadership

translational teams

investors

due diligence teams

Downloads last month: 46

Number of rows:

Total file size:

9.19 kB